Incomplete Freund's adjuvant
- Generic Name
- Incomplete Freund's adjuvant
- Drug Type
- Biotech
- Unique Ingredient Identifier
- Y9DQK7DB5U
HER-Vaxx Plus Chemotherapy Shows Survival Benefit in HER2-Overexpressing Gastric Cancer
• A phase II trial of HER-Vaxx plus chemotherapy demonstrated a 40% survival benefit compared to chemotherapy alone in patients with HER2-overexpressing gastric cancer.
• The HER-Vaxx vaccine induced strong HER2-specific IgG and IgG1 antibody responses, correlating with tumor reduction and inhibition of intracellular phosphorylation.
• The vaccine's mechanism of action includes antibody-dependent cellular cytotoxicity (ADCC) and counteraction of immune tolerance effects, enhancing chemotherapy's impact.
• The study suggests HER-Vaxx is safe and immunogenic, warranting further evaluation in larger trials and combination therapies for advanced gastric cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath